How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity TripletInvestors Business Daily • 10/24/24
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 10/23/24
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?Benzinga • 10/22/24
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?Zacks Investment Research • 10/18/24
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its FutureThe Motley Fool • 10/17/24
Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024PRNewsWire • 10/16/24
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit TherapeuticsThe Motley Fool • 10/13/24
Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALDMarket Watch • 10/09/24
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALDPRNewsWire • 10/09/24
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street AnalystsThe Motley Fool • 10/07/24
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, PfizerInvestors Business Daily • 10/04/24
Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable RisksSeeking Alpha • 09/25/24
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of DataSeeking Alpha • 09/25/24